ERBB2 and breast disorder: The present studies show that in an in vitro system, Th1 cytokines plus the targeted drug, lapatinib, work together to enhance tumor kill, making the combination of lapatinib plus DC-based vaccination against HER-2 an attractive combination to test in the near future for HER-2pos breast disease.